Statements (37)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:abbreviation |
Aptensio Extended Release
|
| gptkbp:activeIngredient |
methylphenidate hydrochloride
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N06BA04
|
| gptkbp:broadcastOn |
gptkb:Schedule_II_controlled_substance
|
| gptkbp:contraindication |
glaucoma
MAOI use tics |
| gptkbp:form |
10 mg
20 mg 40 mg 50 mg 15 mg 70 mg 30 mg extended-release capsule 60 mg |
| gptkbp:genericName |
gptkb:methylphenidate
|
| gptkbp:halfLife |
3-4 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aptensio XR
|
| gptkbp:indication |
ADHD in patients 6 years and older
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
Rhodes Pharmaceuticals
|
| gptkbp:marketedAs |
2015
|
| gptkbp:mechanismOfAction |
stimulant
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
headache
nervousness insomnia decreased appetite increased blood pressure |
| gptkbp:usedFor |
gptkb:attention_deficit_hyperactivity_disorder
|
| gptkbp:bfsParent |
gptkb:methylphenidate
|
| gptkbp:bfsLayer |
6
|